Table 2 Number of novel components of the human exosome targeted by the serum of patients with idiopathic inflammatory myopathy (IIM), scleroderma, or the polymyositis/scleroderma (PM/Scl) overlap syndrome
From: Autoantibodies directed to novel components of the PM/Scl complex, the human exosome
| Â | Â | Number of targeted components per seruma | |||||
|---|---|---|---|---|---|---|---|
Number of reactive serab | Â | 1 | 2 | 3 | 4 | 5 | 6 |
IIM (n = 48) | 30 | 16 | 8 | 3 | 1 | 1 | 1 |
Scleroderma (n = 11) | 8 | 5 | 3 | 0 | 0 | 0 | 0 |
Myositis/scleroderma overlap (n = 10) | 6 | 4 | 1 | 1 | 0 | 0 | 0 |